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Available online xxxxBackground: Radioresistance is the major cause of cancer treatment failure. Additionally, splicing dysregulation
plays critical roles in tumorigenesis. However, the involvement of alternative splicing in resistance of cancer
cells to radiotherapy remains elusive. We sought to investigate the key role of the splicing factor SRSF1 in the
radioresistance in lung cancer.
Methods: Lung cancer cell lines, xenograftmicemodels, and RNA-seqwere employed to study the detailedmech-
anisms of SRSF1 in lung cancer radioresistance. Clinical tumor tissues and TCGA dataset were utilized to deter-
mine the expression levels of distinct SRSF1-regulated splicing isoforms. KM-plotter was applied to analyze
the survival of cancer patients with various levels of SRSF1-regulated splicing isoforms.
Findings: Splicing factors were screened to identify their roles in radioresistance, and SRSF1 was found to be
involved in radioresistance in cancer cells. The level of SRSF1 is elevated in irradiation treated lung cancer
cells, whereas knockdown of SRSF1 sensitizes cancer cells to irradiation. Mechanistically, SRSF1 modulates vari-
ous cancer-related splicing events, particularly the splicing of PTPMT1, a PTEN-like mitochondrial phosphatase.
Reduced SRSF1 favors the production of short isoforms of PTPMT1 upon irradiation, which in turn promotes
phosphorylation of AMPK, thereby inducing DNA double-strand break to sensitize cancer cells to irradiation.
Additionally, the level of the short isoform of PTPMT1 is decreased in cancer samples, which is correlated to can-
cer patients' survival.
Conclusions: Our study provides mechanistic analyses of aberrant splicing in radioresistance in lung cancer cells,
and establishes SRSF1 as a potential therapeutic target for sensitization of patients to radiotherapy.
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m.2018.11.0071. Introduction
Radiotherapy is one of themost effective approaches for cancer ther-
apy. Some complicated biological processes are involved in radiother-
apy to induce cancer cell death [1,2]. Nevertheless, many cancer
patients develop resistance to radiotherapy during treatment, which
may be caused by different factors [3–5]. However, the underlying
mechanisms of the radioresistance development are still elusive.
N95% of human genes undergo alternative splicing (AS) to generate
protein diversity [6]. As one of the most important mechanisms of
gene regulation, AS plays critical roles in modulating protein function
intricately. In addition, AS is tightly regulated in different tissues andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
Research in context
Evidence before this study
Splicing dysregulation plays critical roles in tumorigenesis.
Radioresistance is the major cause of cancer treatment failure.
However, the involvement of alternative splicing in resistance of
cancer cells to radiotherapy remains elusive.
The value of this study
This study aimed to investigate whether the splicing factor
SRSF1 is involved in radioresistance in lung cancer. We found
that the splicing of PTPMT1 is modulated by SRSF1. The splicing
switch towards the short isoform of PTPMT1 leads to the in-
creased phosphorylation of AMPK, which sensitizes lung cancer
cells to radiotherapy.
Implications of all the available evidence
Our study providesmechanistic analyses of deregulated splicing in
radioresistance in lung cancer, and establishes SRSF1 as a poten-
tial therapeutic target for sensitization of patients to radiotherapy.
2 J. Sheng et al. / EBioMedicine xxx (xxxx) xxxdevelopmental stages, and commonly controlled by various splicing fac-
tors, including serine/arginine-rich (SR) proteins. Importantly, deregu-
lation of AS can lead to cancer [7–10]. Certain splicing isoforms of
cancer related genes can function as molecular markers of cancer [11],
or directly regulate cancer initiation and progression [12].
Aberrant expression of splicing factors is one of the main causes
of splicing deregulation in cancer [13–16]. For example, the splicing
factor SRSF1 is a crucial family member of SR proteins. SRSF1 usu-
ally binds to exonic splicing enhancers to promote splicing, however
it binds to intronic elements to inhibit splicing [17,18]. In addition
to splicing regulation, SRSF1 was also reported to participate in mul-
tiple biological functions, including translation control, nonsense-
mediated RNA decay (NMD), RNA transport, and senescence
[19–22]. SRSF1 can interact with translating ribosomes and promote
translation [23]. Moreover, the mRNA translational targets of SRSF1
were systematically identiﬁed to be involved in cell cycle regulation
[24]. SRSF1also increases the binding of NMD factor UPF1 to mRNAs,
thereby bypassing UPF2 recruitment and promoting NMD [25].In ad-
dition, SRSF1 stabilizes p53 through blocking its MDM2-dependent
proteasomal degradation, thus to result in oncogene-induced senes-
cence (OIS) [22]. Strikingly, SRSF1 has been identiﬁed as a potential
oncogene that is overexpressed in several cancers [26–28]. The ele-
vated expression of SRSF1 results, in cooperation with MYC, in the
transformation of mammary epithelial cells [28]. Moreover, SRSF1
regulates the epithelial-to-mesenchymal transition (EMT) through
modulating the splicing of Ron proto-oncogene [29], as well as con-
trols the alternative splicing of PRRC2C and MKNK2 to regulate lung
cancer progression [28,30].Most importantly, SRSF1 regulates the
splicing of BIM to inhibit imatinib-induced apoptosis, thereby con-
ferring cancer cells resistance to imatinib [31]. In addition, other
splicing factors, such as hnRNP A1 and PTB, have been reported to
inﬂuence pyruvate kinase splicing and cell metabolism to affect tu-
morigenesis [32], whereas RBM4 controls the alternative splicing of
Bcl-x to inhibit lung cancer progression [14]. Therefore, speciﬁcally
targeting deregulated AS may provide a novel avenue for cancer
therapy [33].
In this study, we screened splicing factors that might participate in
radioresistance regulation, and found levels of SRSF1 is markedly in-
creased in radioresistant cells. In addition, increased levels of SRSF1
are examined in lung cancer cells that are treated with ionizingPlease cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.007radiation, suggesting that SRSF1 might play key roles in radioresistance
in lung cancer.Meanwhile, depletion of SRSF1 could signiﬁcantly induce
DNA damage, and apoptosis of cancer cells upon irradiation. Mechanis-
tically, knockdown of SRSF1 favors the production of short isoforms of
PTPMT1, thereby inducing the phosphorylation of AMPK and sensitizing
cancer cells to radiotherapy. Our study highlights the importance of
SRSF1 as a potential therapeutic target to sensitize cancer patients for
radiotherapy.
2. Materials and methods
2.1. Cell culture and transfection
All cell lines used in our study were purchased from American Type
Culture Collection (Manassas, VA, USA). The human embryonic kidney
HEK293T (Cat# CRL-11268, RRID: CVCL_1926) cells were maintained
in DMEM (high glucose) medium with 10% fetal bovine serum (FBS,
Hyclone) and 1% penicillin/streptomycin (P/S), in humidiﬁed 5% CO2
at 37 °C. The human non-small lung carcinoma cell line A549 (Cat#
CRM-CCL-185, RRID: CVCL_0023) was maintained in F-12 K medium
with 10% FBS and 1% P/S, in humidiﬁed 5% CO2 at 37 °C. The H1299
(Cat# CRL-5803, RRID: CVCL_0060) human lung carcinoma cells were
cultured in RPMI-1640 medium containing 10% FBS and 1% P/S, in hu-
midiﬁed 5% CO2 at 37 °C.
To generate H1299 and A549 cell lines stably knocking-down SRSF1,
lentiviral particleswere produced by transient transfection of HEK293 T
cells with pLKO-SRSF1-sh1 or pLKO-SRSF1-sh2 or pLKO-empty vectors
according to manufactures protocols. 72 h after transfection, the super-
natant media containing lentivirus was collected and incubated with
H1299 and A549 cells for 24 h in normal medium containing 8 μg/mL
Polybrene (Sigma). Then stably integrated cells were selected by 5
μg/mL puromycin for one week. All cell lines were conﬁrmed by west-
ern blots before further analysis.
To stably express PTPMT1A or PTPMT1B in H1299 cells, we used
lentiviral vectors as well. Brieﬂy, HEK293T cells were transiently
transfected with pCDH-HA-PTPMT1A or pCDH-HA-PTPMT1B or pCDH-
HA-empty vectors according to manufactures protocols. The superna-
tant media containing lentivirus was collected and used to infect
H1299 cells, followed by 5 μg/mL puromycin selection for one week.
The stable expression cell lines were conﬁrmed bywestern blots before
further analysis.
To determine the localization of PTPMT1A or PTPMT1B, we
transfected 1 μg of HA-tagged PTPMT1A or PTPMT1B vectors in H1299
cells using lipofectamine 3000 according to the manual. 48 h later,
H1299 cells were ﬁxed for further immunoﬂuorescence analysis.
In order to examine the effect of over-expression of SRSF1 on
PTPMT1 splicing changes, we co-transfected 0.2 μg of PTPMT1 mini-
gene reporters with 0.4 μg of SRSF1 using lipofectamine 3000 according
to the manual. Cells were collected for further analysis of RNA level at
48 h after transfection.
2.2. Splicing reporter constructs
To construct the PTPMT1 reporter, the fragment containing exon 2,
part of intron 2, exon 3, part of intron 3, and exon 4 of PTPMT1 were
cloned into EcorI and NotI sites of pCDNA3.1(+) vector. To mutate
SRSF1 binding sites of PTPMT1 reporters, overlapping PCR was used
with different paired primers. The primers used for plasmid construc-
tion were listed in Supplemental Table 1.
2.3. Real-time cell analysis (RTCA) experiments
Cell proliferation assays were performed using xCELLigence Real-
Time Cell Analyzer RTCA-MP system (Acea Biosciences/Roche Applied
Science). Add 50 uL RPMI 1640 media with 10% FBS to each well of E-
Plate 96 (Roche Applied Science) to obtain equilibrium. H1299 cellsTPMT1 alternative splicing to regulate lung cancer cell radioresistance,
3J. Sheng et al. / EBioMedicine xxx (xxxx) xxxtransfected PTPMT1 B were collected and the concentration of the cell
suspensions were adjusted to 2 × 104 cells/mL. Add 100 μL of cell sus-
pension to each well of E-Plate 96. Impedance readings were taken au-
tomatically every 15min until the end of the experiment and plotted as
Cell Index ± SD.Please cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.0072.4. Cell proliferation assay
H1299-SRSF1-shcells and control cellswere seeded in 96-well plates
at1000cells perwell andgrown for 8days. Cell numbersweremeasured
using CCK-8 (Beyotime) at 0, 2, 4, 6 and 8 day after incubation.TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
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The total RNAswere extracted from transfected cells using TRIzol re-
agent (Invitrogen) according to the manufacturer's protocol. Genomic
DNA were removed by 1 h DNase I (Invitrogen) treatment at 37 °C.
Total RNA (2 μg) was then reverse-transcribed into cDNA with Super-
Script III (Invitrogen) using poly T primer, and one-tenth of the resulting
cDNA was used as the template for PCR ampliﬁcation (25 cycles of am-
pliﬁcation). RT-PCR products were separated on 3% agarose gels, and
imaged were captured using a CCD camera (Tanon 2500R). The quanti-
ﬁcation of mRNA isoforms was achieved by comparison of the inte-
grated optical density of detected bands measured by the GIS 1D Gel
Image System (ver. 4.2; Tanon).2.6. Western blot
Cells were washed twice with cold PBS and then lysed in lysis buffer
(50 mM HEPES, 150 mM NaCl (4.38 g), 1 mM EDTA, 1% (w/v) CHAPS
and Sigma protease inhibitor cocktail). The cell lysateswere centrifuged
at 12000 rpm for 15 min and the protein concentration was measured
using Coomassie protein assay kit. Equal amounts of total protein
were resolved by 10% SDS-PAGE and transferred to nitrocellulosemem-
brane. All primary antibodies were diluted 1000 times for WB if not
speciﬁed. The following antibodies were used in this study: SRSF1
(#sc-33,652, RRID: AB_628248) antibody was purchased from SCBT.
Anti-HA tag antibody (#mms-101p-1000, RRID: AB_291259) were pur-
chased from Convance. Alpha-tubulin (#T5168, RRID: AB_477579,
1:5000 dilution) was purchased from Sigma-Aldrich. Bound antibodies
were visualized with the ECL kit (GE Healthcare).2.7. Assay of SRSF1 expression with Realtime PCR
We performed the real-time PCR using the Maxima SYBR Green
qPCR Master Mix (Thermo Scientiﬁc) and a 7500 real-time PCR system
(Life Technologies) according to manufacturer's instructions. The ex-
pression level of SRSF1 was normalized to the endogenous expression
of GAPDH.2.8. Heat map
We kept genes: i) FPKM (Fragments Per Kilobase of transcript per
Million mapped reads) values of one gene are not equal in all samples;
ii) At least one of the FPKM values in all samples is larger than or equal
to 3; iii) The ratio of maximum FPKM value and minimum FPKM value
in all samples is larger than or equal to 2. The log 2 ration of FPKMvalues
of kept genes which normalized by the FPKM value of control sample
were used as input of Cluster 3.0 (de Hoon, et al., 2004). Then we used
hierarchical clustering method based on Pearson correlation with aver-
age linkage to cluster the dataset, and further viewed the results with
Java TreeView. We selected the cluster in this pattern regulated by
SRSF1 with or without ionizing radiation as our target dataset.Fig. 1. Reduction of SRSF1 sensitizes lung cancer cells to IR. (a) Heat map depicting gene express
of SRSF1 was examined in H1299 and A549 cells that were treatedwith orwithout IR. (c) Colon
or without IR treatment. Images of the whole plate are shown. Three experiments were condu
performed using H1299 cells with depletion of SRSF1 or control with or without IR. Thr
(e) Apoptosis of H1299 cells with downregulation of SRSF1 or control combined with or with
± SD of apoptotic cells plotted. (f) Clonogenic survival was examined in colony formation ass
IR. Three experiments were performed with corresponding data normalized to each contr
different times after IR (at 0, and 2 h). Immunoﬂuorescence staining for γ-H2AX followed by
foci were counted as positive and 300 cells were counted. Representative images of γH2AX fo
shown. Scale bar = 50 μm. (h) Western blot was performed to measure the levels of p-Chk2
knockdown and control H1299 cells upon IR. Comet images of DSBs detected by single cell gel
DSBs. 100 individual comets were counted per time point for each experiment. The tail m
independent experiments. Data are shown as mean values ± S.D. from three independent exp
Please cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.0072.9. Ionizing radiation treatment
H1299-SRSF1-sh cells or control cells grown on 10 cm plates with
liquid culture media were irradiated with ionizing radiation using an
X-RAD 320ix Biological Irradiator (Precision X-ray Inc.). The cells were
treated 50 cm from the source of radiation (SSD) with a dose of 6 Gy.
The cells were treated at room temperature.
2.10. Colony formation assay
H1299 cells (or A549 cells) knocking-down SRSF1 or expressing
PTPMT1A, PTPMT1B, and control vectors (1000 cells per dish) were
grown in the 10-cmdishes and incubated at 37 °C in humidiﬁed incuba-
tor for 9 days. Colonies were ﬁxed with methanol at room temperature
and stained with crystal violet followed by washing with water and
photographed.
2.11. Mouse irradiation study
H1299 cells stably expressing PTPMT1B or control (1 × 106) were
suspended in 100 μL of PBS and were injected subcutaneously into the
abdomen side of 6-week-old BALB/c nude mice. Macroscopic observa-
tion and tumor volume measurements were performed every 3 days.
When tumors reached the volume of approximately 250mm3, the
mice (six per treatment group) were exposed to 6 Gy radiation. After
IR, tumor volume measurements were performed every 2 days. Tumor
volume was calculated according to the following formula: tumor vol-
ume (mm3) = length (mm) × (width (mm))2/2. The body weight dur-
ing the course of the study were measured every 3 days or 2 days. All
animals were sacriﬁced 40 days after injection and excised tumors
were weighed. The animal experiments were strictly compliant with
the animal care guidelines of Dalian medical university.
2.12. Clinical tissues samples collection
We collected fresh lung cancer tissues and adjacent normal tissues
from patients with pathologically and clinically conﬁrmed lung carcino-
mas. All human tumor tissues were obtained with written informed
consent from patients or their guardians prior to participation in the
study. Use of the tumor specimens in this studywas approved by the In-
stitutional Review Board of the Dalian Medical University. All of tissue
specimens were immediately frozen in liquid nitrogen and kept at
−80 °C until the extraction of protein or mRNA.
2.13. High throughput mRNA-sequence and data analysis
Total RNAs of H1299 cells stably knocking-down SRSF1, and control
vectors with or without treatment of ionizing radiation were isolated
using Trizol™ method and subsequently cleaned using RNAeasy Kit
(Qiagen). The DNA was removed from total RNAs by digesting in col-
umn with RNAse free DNAse according to manufacturer's instruction.
Illumina TruSeq Total RNA Sample Prep kits were used to further purify
polyadenylated RNA from total RNA. Ribosomal RNA was removed by
Epicentre Ribo-zero™ rRNA removal Kit (Epicentre, USA). RNA-seqion of splicing factors in radiosensitive and radioresistant cancer cells. (b) The protein level
y formation assays using H1299 cells with knock down of SRSF1 or control combinedwith
cted with mean ± SD of relative colony numbers plotted. (d) Growth curve assays were
ee experiments were carried out with mean ± SD of relative cell numbers plotted.
out IR were evaluated by ﬂow cytometry. Three experiments were conducted with mean
ays in H1299 cells with knock down of SRSF1 or control treated with different dosages of
ol and expressed as mean ± SD. (g) SRSF1 knockdown and control cells were ﬁxed at
confocal microscopy was performed to analyze γ-H2AX foci after IR. Cells displaying N10
ci and the percentage of SRSF1 knockdown and control cells displaying γH2AX foci were
and γ-H2AX in H1299 cells with knockdown of SRSF1 upon IR. (i) Comet assay of SRSF1
electrophoresis at 0.5 h after IR are shown. The tail moment was used as the endpoint of
oments were measured and data were represented as the mean tail moment from 3
eriments. For all panels “*” indicates p b 0.05.
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6 J. Sheng et al. / EBioMedicine xxx (xxxx) xxxlibraries were generated with the rRNA-depleted RNA by NEBNext
Ultra™ Directional RNA Library Prep Kits (NEB, USA) according to the
manufacturer's protocol. The RNA-seq experiments were performed
by Novogene. The RNA-seq dataset was deposited to the Gene Expres-
sion Omnibus with accession number GSE107224.
To estimate the gene expression levels, RSEM package and bowtie2
(Li and Dewey, 2011) (Langmead and Salzberg, 2012) were used to
align all reads to human reference genome (UCSC hg19 version). To cal-
culate transcript expression levels, we provided a fragment length dis-
tribution with options of “–fragment-length-mean 75” and “–
fragment-length-sd 10”. Subsequently EBSeq tool (Leng, et al., 2013)
were used to examine differential expression genes of pairwise compar-
ison according to empirical Bayesian methods.
We mapped the paired-end sequences to human genome (hg19)
using MapSplice 2.0.1.6 (default parameters) to discover splicing junc-
tions. To calculate the level of gene expression, we further analyzed
the mapped reads using Cufﬂinks. Then we used MISO package with
the annotation of all known alternative splicing events [34] to analyze
the change of splicing isoforms, and we ﬁltered the results based on
the PSI (percent spliced in) values.
We performed gene ontology enrichment analysis using DAVID GO
analysis software to search for enriched pathways. We also analyzed
the functional association of SRSF1 targets using protein interaction
data from STRING database, generating a set of functional interaction
networks. The sub-network containing more than ﬁve nodes were
demonstrated.
2.14. RNA immunoprecipitation
H1299 cells expressing Flag-SRSF1 or control vector are harvested by
trypsinization and resuspended in 10 mL PBS. Formaldehyde (37%
stock) is added to the cells to a ﬁnal concentration of 1% and incubated
at room temperature for 10 min with slow rotating. Crosslinking reac-
tions are blocked by the addition of glycine solution (pH 7.0) to a ﬁnal
concentration of 0.25 M followed by incubation at RT for 5 min. After
two washes with ice-cold PBS, the cells are collected by centrifugation
at 3000 rpm for 4 min at 4 °C and resuspended in 2 mL of RIPA buffer
(50 mM Tris-Cl, pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.05%
SDS, 1 mM EDTA, 150 mM NaCl) containing protease inhibitors. After
three rounds of sonication, solubilized cell lysate was precleared by
mixing with M2-Flag beads along with nonspeciﬁc tRNA, and collected
for immunoprecipitation. The precleared lysate was diluted with RIPA
buffer, and immunoprecipitated by incubating with M2-Flag beads for
60–90 min, followed by ﬁve or six times washes with 1 mL of RIPA
buffer (50 mM Tris-Cl, pH 7.5, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, 1 mM EDTA, 1 M NaCl, 1 M Urea, 0.2 mM PMSF). The beads
were resuspended in 100 μL of 50 mM Tris-Cl, pH 7.0, 5 mM EDTA,
10 mM dithiothreitol (DTT) and 1% SDS and incubated at 70 °C for
45min to reverse the crosslinks. The RNAwas extracted with Trizol fol-
lowing the manufacturer's protocol, and reverse transcribed into cDNA
for PCR detection.
2.15. Comet assay
Cells were collected, suspended in PBS at 1 × 105. Mix 25 μL cell sus-
pension with 75 μL Low melting point agarose spread onto a normal
melting point agarose-coated slid. After the agarose solidiﬁed, the slides
were placed in Lysing solution(2.5 mol/L NaCl,100 mmol/L EDTA-
Na2,10 mmol/L tris, 1% Triton X-100 and 10% DMSO) for 2 h. The slidesFig. 2.Global transcriptional identiﬁcation of genes regulated by SRSF1 after IR. (a) Gene ontolo
for each category. (b) The analyses of functional association networks of SRSF1-regulated gene
(c) The identiﬁed gene expression changes were validated by qRT-PCR. The mean ± SD of re
paired t-test. (d) GO analyses of SRSF1-regulated AS events. Fisher exact p values were plotted
events were performed using the STRING database, with subgroups marked by their functions
from triplicate experiments were plotted with p values calculated by paired t-test.
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After electrophoresis, drain the slides on tissue paper and ﬂood with
buffer for 3 times, each time 5 min. Cells were stained with DAPI and
measured in a ﬂuorescent microscope.
2.16. Immunoﬂuorescence staining
Transfected cells with appropriate density were ﬁxed on the cover-
slips with 4% paraformaldehyde in 1× PBS for 15 min at room tempera-
ture and washed with 1× PBS three times. Cells were then
permeabilized with 0.2% Triton X-100 for 10 min and washed with 1
× PBS three times. After blocking in 3% BSA for 30min, slideswere incu-
bated with indicated antibodies (p-H2AX, SRSF1, or HA, 1:100 dilution)
antibody diluted in 3% BSA for 2 h. Subsequently, slides were rinsed
three times with 1× PBS for 5 min each and then incubated with
ﬂuorophore-conjugated secondary antibodies for 1 h. The cover slips
were then washed with 1× PBS for three times and mounted with
mounting medium (Vector shield's mounting medium with DAPI).
Cells were visualized using an Olympus ﬂuorescence microscope, and
photographs were captured using a Kodak digital camera.
2.17. Statistics
Student's t-test was used for statistical analyses of colony formation,
soft agar, and splicing changes.
2.18. Data availability
RNA-seq data in this study have been deposited in Gene Expression
Omnibus of NCBI with the accession code GSE107224. The authors de-
clare that all the data supporting the ﬁndings of this study are available
within the article and its Supplemental information ﬁles.
2.19. Study approval
The Institutional Animal Care and Use Committee of theDalianMed-
ical University approved use of animal models in this study. Informed
consent was taken from patients or their guardians prior to participa-
tion in the study. Approved use of the tumor specimens in this study
was obtained from the Institutional Review Board of the DalianMedical
University.
3. Results
3.1. SRSF1 regulates response to irradiation via modulating DNA double-
strand break
Radiotherapy is one of themost effective approaches for cancer ther-
apy, however, cancer cells could develop resistance to radiotherapy and
the molecular mechanisms underlying this phenomenon remains un-
clear. Additionally, the role of aberrant splicing in radioresistance is
also elusive.
In order to investigate the role of alternative splicing in
radioresistance of cancer cells, we analyzed the data from a published
gene expression proﬁle for radioresistance related genes (GSE20549)
to identify splicing factors involved in this process. Interestingly, we
found SRSF1 is oneof the top hits among radioresistance related splicing
factors, which is elevated in radioresistant cancer cells (Fig. 1a).SRSF1
has been identiﬁed as a potential proto-oncogene that modulatesgy analyses of SRSF1-regulated gene expression events. Fisher exact p values were plotted
s were performed using the STRING database, with subgroups marked by their functions.
lative fold changes from triplicate experiments were plotted with p values calculated by
for each category. (e) Analysis of functional association networks of SRSF1-regulated AS
. (f) Selected AS events were validated by RT-PCR. The mean ± SD of relative PSI changes
TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
Fig. 3. SRSF1 regulates theASof PTPMT1. (a) The splicing of PTPMT1wasmeasuredwith RT-PCR inH1299 cellswith knockdownof SRSF1 or control, andH1299 cells overexpressing SRSF1
or control. The level of SRSF1 was evaluated by western blot. (b) A schematic of PTPMT1 pre-mRNA where the potential SRSF1-binding sites are labelled. PTPMT1 splicing reporters with
the indicatedmutations (mut1 to 5)were generated. The splicing of thewild type PTPMT1 reporter weremeasured inH1299 cells with knock down of SRSF1or control, and inH1299 cells
overexpressing SRSF1 or control vector, using RT-PCR. (c) PTPMT1 splicing reporters containing variousmutationswere co-expressedwith SRSF1 or control inH1299 cells to assay splicing
change in PTPMT1. The mean± SD of PSI was plotted. A representative gel from triplicate experiments was shown. (d) Binding of PTPMT1 pre-mRNAs with SRSF1 is detected by RNA-IP
assay in cells exogenously expression FLAG-SRSF1 or control. (e) H1299 cells were co-transfected with Flag-SRSF1 or control and the indicated mutant or wild-type (WT) PTPMT1
reporters, and then immunoprecipitated with anti-Flag antibody. The co-precipitated RNAs were detected by RT-PCR.‘*’ indicated a non-speciﬁc band.
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confers resistance to chemotherapy on cancer cells [35]. Consistently,
the levels of SRSF1were elevated after ionizing radiation (IR) treatment
in both H1299 and A549 cells (Fig. 1b), suggesting that SRSF1 might be
involved in the radioresistance of lung cancer cells. To further test this
possibility, we stably knocked down SRSF1 in NSCLC cells and examined
whether the reduction of SRSF1 could affect cell viability after IR
(Fig. S1a).Strikingly, downregulation of SRSF1 inhibited clonogenic sur-
vival of lung cancer cells after IR treatment as compared to control in
two different NSCLC cell lines (H1299 and A549) (Fig. 1c–d and
Fig. S1b–c).
Ionizing radiation induces apoptosis in cancer cells. We found that
lung cancer cells with decreased SRSF1 displayed a signiﬁcantly ele-
vated rate of apoptosis compared to controls, particularly upon IR
(Fig. 1e and Fig. S1d).Moreover, colony formation assays conﬁrmed
that inhibition of SRSF1 signiﬁcantly increased the sensitivity to IR in
two tested lung cancer cell lines (Fig. 1f and Fig. S1e).
To better understand the detailed mechanisms underlying SRSF1-
induced radioresistance in lung cancer cells, we measured γH2AX foci
formation (indicative of double-strand breaks) [36] by immunoﬂuores-
cence staining after IR.As shown in Fig. 1g and Fig. S1f, the number of
γH2AX foci in SRSF1 knockdown cells were markedly increased, indi-
cating an elevated degree of DNA damage in these cells compared to
that in control cells. Meanwhile, the expression level of p-Chk2, another
DNA double-strand break marker, was also evidently induced in SRSF1
knockdown cells after IR compared to control (Fig. 1h).Further evalua-
tion of DNA double-strand breaks using COMET assays revealed a signif-
icant increase in DNA damage in SRSF1 knockdown cells upon
irradiation (Fig. 1i and Fig. S1g).Altogether, our data suggest that loss
of SRSF1 may lead to radiosensitization through enhancing DNA
double-strand break.
3.2. Global transcriptional identiﬁcation of genes regulated by SRSF1
after IR
To mechanistically study how SRSF1 impacts tumorigenesis in re-
sponse to IR, we examined the transcriptomes of control and SRSF1 sta-
bly knocking down H1299 cells treated with or without IR by RNA-seq
(Fig. S2a). We further applied gene ontology analysis, and found thatPlease cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.007these genes are signiﬁcantly associated with cancer related functions,
including cell cycle regulation, cell adhesion, cell proliferation and regu-
lation of gene expression (Fig. 2a).
We next performed network analysis using the STRING database to
evaluate the interaction of these responsive transcripts (Fig. 2b). Strik-
ingly, the gene-set form a densely-connected network, and one of the
largest clusters of genes contains some key regulators of cell prolifera-
tion (e.g., NOTCH1, TGM2, and so on). In addition, these genes also in-
clude components of signaling pathways that affect catalytic activity
(e.g., MAP4K4, MTOR, and so on).
Subsequently, we randomly selected six cancer-related target
genes, and tested the RNA-seq results with qRT-PCR. As expected,
these events can be validated in both H1299 and A549 cells (Fig. 2c
and Fig. S2b).
Next we sought to determine the SRSF1-regulated AS events that
may play vital roles in modulating the radioresistance of cancer cells.
We identiﬁed 42 SRSF1-regulated AS events with an obvious change
of percent-spliced-in (PSI) that were overlapped in samples with or
without IR treatment (Fig. S2c).When analyzing cellular functions of
SRSF1-regulated AS events that differentially expressed after IR, we uti-
lized gene ontology approach and found that after IR,SRSF1 affects
genes in RNA processing pathway including translational initiation,
mRNA catabolic process, and translational elongation (Fig. 2d). Intrigu-
ingly, SRSF1 targeted genes are enriched with tumorigenesis-related
functions such as cell-cell adhesion (Fig. 2d). In addition, the majority
of SRSF1-controlled AS events were functionally connected into well-
linked interaction networks (Fig. 2e). Two of the large subgroups of
SRSF1 targets include genes in cell-cell adhesion and mitochondrial
ATP synthesis (Fig. 2e). Taken together, these data imply the biological
processes inﬂuenced by SRSF1 after IR are highly associated with cell
proliferation, cell adhesion, and mitochondrial functions.
We further validated the RNA-seq results by determining splicing
changes for 6 identiﬁed targets, which were arbitrarily selected to in-
clude genes with cancer related function. We used two cell lines
(H1299 and A549), and conﬁrmed that SRSF1 regulates all tested en-
dogenous AS events, including splicing of IRF3, PTPMT1, NGFRAP1,
MRPS28, KRIT1, and FBXO38 (Fig. 2f and Fig. S2d). Together, our results
suggest that SRSF1 may modulate the radiosensitivity of cancer cells
through controlling AS of cancer related genes.TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
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Since mitochondrial ATP synthesis is one of the key biological pro-
cesses affected by SRSF1 after IR. We focused on PTPMT1, a PTEN-like
mitochondrial phosphatase, whose splicing has been signiﬁcantly af-
fected upon depletion of SRSF1 after irradiation.PTPMT1 has two splic-
ing isoforms, including the canonical full-length A isoform and a short
B isoformwithout exon 3 (Fig. S3a).To investigate whether SRSF1 regu-
lates PTPMT1 splicing, we tested if changes of SRSF1 expression could
affect PTPMT1 splicing. We found that depletion of SRSF1 shifts the
full-length PTPMT1A towards the short isoform PTPMT1B in both
H1299 and 293T cells (Fig. 3a and Fig. S3b–c).Conversely, overexpres-
sion of SRSF1 switched the splicing to PTPMT1A (Fig. 3a and Fig. S3c).
Further analyses revealed that these two PTPMT1 isoforms have similar
subcellular localizations, with both PTPMT1A and PTPMT1B are primar-
ily located in the cytoplasm (Fig. S3d). Therefore, SRSF1 is able to regu-
late the splicing of PTPMT1.
We next examined if SRSF1 directly regulates the splicing of
PTPMT1. Bioinformatics analyses(ESE Finder) identiﬁed several poten-
tial SRSF1 binding sites within the alternatively spliced exon 3 of
PTPMT1 (Fig. 3b), suggesting that SRSF1 may regulate splicing through
directly binding to PTPMT1 pre-mRNA. To test this possibility, we gen-
erated a splicing reporter containing PTPMT1 pre-mRNAwith predicted
SRSF1 binding sites (Fig. 3b and Fig. S3e) [37]. Consistent with results of
the endogenous transcript, knockdown of SRSF1 shifted the splicing of
wild-type reporter from PTPMT1A to PTPMT1B (PSI changed from 81%
to 72%) (Fig. 3b), and overexpression of SRSF1 switched the splicing to-
wards PTPMT1A (PSI changed from 77% to 87%) (Fig. 3b).
To directly test the role of these potential SRSF1 binding sites in
SRSF1- mediated PTPMT1 splicing, we generated multiple splicing re-
porters containing mutations of the potential SRSF1 binding sites
(Fig. 3b). Interestingly, although individualmutants that bearmutations
on four of these predicted SRSF1 binding sites failed to alter the splicing
of PTPMT1 (Fig. 3C, mut1 tomut4), mutations on the GTACCAGTCG site
(mut 5)partially abolished the SRSF1-mediated splicing of PTPMT1, in-
dicating that the potential binding motif is partially responsible for the
PTPMT1 splicing switch (Fig. 3c).In addition, by using an RNA-IP ap-
proach, we found that SRSF1 does speciﬁcally bind to the endogenous
PTPMT1 pre-mRNA (Fig. 3d).Further RNA-IP assays with wild type or
mutated reporters showed that the SRSF1 binding is indeed dependent
on the GTACCAGTCG site, as mutation of this site almost completely
prevented the interaction of SRSF1 with the PTPMT1 pre-mRNA
(Fig. 3e and Fig. S3f). Collectively, our data demonstrate that SRSF1 di-
rectly binds to the alternative exon region of PTPMT1 to control its
splicing.
3.4. PTPMT1 splicing switch sensitizes lung cancer cells to IR
To studywhether SRSF1-mediated splicing of PTPMT1 contributes to
the increased radiosensitivity of cancer cells upon SRSF1 knockdown,
we evaluated the impact of the splicing switch, which favors the pro-
duction of PTPMT1B, on radioresistance of cancer cells. We generated
H1299 cells stably expressing PTPMT1B, and the overexpressedFig. 4. PTPMT1 splicing switch induces DNA damage. (a) Clonogenic survival was examined i
treated with different dosages of IR. The mRNA expression levels of PTPMT1B were examin
normalized to each control and expressed as mean ± SD (* indicated p b 0.05). (b) Growth c
PTPMT1B or control that were treated with or without IR. (c) H1299 cells with ectopic ex
Immunoﬂuorescence assay for γ-H2AX followed by confocal microscopy was performed to ev
the percentage of ectopic expression of PTPMT1B and control cells displaying γ-H2AX foci we
and γ-H2AX in H1299 cells with ectopic expression of PTPMT1B or control upon IR. (e) Come
DSBs detected by single cell gel electrophoresis at 0.5 h after IR are shown. Data are shown a
determined in colony formation assays in H1299 cells with knocking down SRSF1 or contr
different dosages of IR. The mRNA expression levels of PTPMT1A were examined with realtim
each control and expressed as mean ± SD. (g) H1299 cells with depletion of SRSF1 or contro
after IR (at 0 and 2 h) and immuno-stained for γ-H2AX foci. Representative images of γ-H2A
(h) Western blot was applied to determine the levels of γ-H2AX in H1299 cells with depleti
without IR. For all panels “*” indicated p b 0.05.
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judged by realtimeRT-PCR, suggesting that the overexpressed PTPMT1B
level is similar to the level of PTPMT1B that can be achieved by SRSF1-
manipulated splicing (Fig. 4a).We further applied colony formation as-
says after different dosages of IR to analyze the relationship between
PTPMT1B and the cellular response to IR. Remarkably, lung cancer
cells stably expressing PTPMT1B signiﬁcantly increased sensitivity to
IR as compared to control (Fig. 4a). Moreover, PTPMT1B displayed a
substantially enhanced ability to inhibit cancer cell proliferation than
control, particularly when cells were treated with IR (Fig. 4b), and
PTPMT1B induced elevated DNA damage upon IR compared to control
(Fig. 4c).Consistently, the level of Chk2 and γH2AX were dramatically
increased by PTPMT1B after IR (Fig. 4d). COMET assays also conﬁrmed
that cells expressing PTPMT1B had increased DNA double-strand breaks
upon IR compared to control (Fig. 4e). Similarly, we found that speciﬁc
knockdown of PTPMT1A signiﬁcantly inhibited cancer cell growth, es-
pecially upon ionizing treatment (Fig. S4a–c). Conversely, re-
expression of PTPMT1A in SRSF1 knocking-down cells signiﬁcantly
inhibited DNA damage upon IR (Fig. 4f–h and Fig. S4d).Taken together,
our results indicate that the splicing switch of PTPMT1 can sensitize
cancer cells to IR and suggest that depletion of SRSF1 sensitizes cancer
cells to radiotherapy through increased splicing of PTPMT1B.
3.5. PTPMT1 splicing induces the expression of p-AMPK to increase
radiosensitivity
To further evaluate the importance of SRSF1-mediated PTPMT1
splicing in regulating the radiosensitivity of cancer cells, we dissected
the possible molecular mechanisms underlying this axis of SRSF1-
PTPMT1. It has been previously reported that AMPK was highly acti-
vated in PTPMT1 knockout cells [38]. Importantly, we found that the
p-AMPK level was markedly elevated upon IR in SRSF1 knockdown
cells as compared to control (Fig. 5a).Consistently, upon irradiation,
PTPMT1B overexpressed cells demonstrated an evidently increased
p-AMPK level, as well as the corresponding changes of its downstream
targets, including elevated p21 and p27 levels, and decreased p-mTOR
level (Fig. 5b).
Further clonogenic survival assays revealed that knockdown of
AMPK in SRSF1-depleted cells reversed the radiosensitization of cancer
cells, as reduced levels of AMPK in SRSF1 knockdown cells promoted the
survival of cells, thereby conferring the cancer cells radioresistance
(Fig. 5c). Moreover, the decreased level of AMPK can also signiﬁcantly
inhibit DNA double-strand break in SRSF1 knockdown cells when
treated with IR (Fig. 5d and e).
3.6. PTPMT1 splicing induces radiosensitivity in vivo and is correlated with
survival
To directly testwhether SRSF1 knockdown increases radiosensitivity
through regulating PTPMT1 splicing in vivo, we treated nudemice bear-
ing xenografts from H1299-PTPMT1B, or H1299-control with or with-
out IR. Strikingly, overexpression of PTPMT1B combined with IR
signiﬁcantly suppressed tumor growth (Fig. 6a–c). In addition, then colony formation assays in H1299 cells with ectopic expression of PTPMT1B or control
ed with realtime RT-PCR. Three experiments were carried out with corresponding data
urve assays were performed to evaluate the proliferation of H1299 cells overexpressing
pression of PTPMT1B or control were ﬁxed at different times after IR (at 0, and 2 h).
aluate γ-H2AX foci at different times after IR. Representative images of γ-H2AX foci and
re shown. Scale bar = 50 μm. (d) Western blot was used to examine the levels of p-Chk2
t assay of H1299 cells with expression of PTPMT1B or control upon IR. Comet images of
s mean values ± S.D. from three independent experiments. (f) Clonogenic survival was
ol, and re-expressing PTPMT1A in SRSF1 depleted condition, which were treated with
e RT-PCR. Three experiments were performed with corresponding data normalized to
l, and re-expression of PTPMT1A in SRSF1 depleted status were ﬁxed at different times
X foci and the percentage of cells displaying γ-H2AX foci are shown. Scale bar = 50 μm.
on of SRSF1 or control, and re-expression of PTPMT1A in SRSF1 depleted status with or
TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
Fig. 5. PTPMT1 splicing induces the expression of p-AMPK to increase radiosensitivity. (a) Western blots were performed to examine the protein levels of p-AMPK in H1299 cells with
knockdown of SRSF1 or control at 0, 1, 6, 12, 24 h after IR. (b) The protein levels of p-AMPK and its downstream targets were measured in H1299 cell with ectopic expression of
PTPMT1B or control. (c) Clonogenic survival was examined in colony formation assays in H1299 cells stably expressing SRSF1 sh1 and control sh2, SRSF1 sh1 and AMPK sh1, SRSF1
sh1 and AMPK sh2, or control sh1 and control sh2 treated with different dosages of IR. Three experiments were carried out with corresponding data normalized to each control and
expressed as mean ± SD. (d) H1299 cells stably expressing SRSF1 sh1 and control sh2, SRSF1 sh1 and AMPK sh1, SRSF1 sh1 and AMPK sh2, or control sh1 and control sh2 were ﬁxed
at different times after IR (at 0, and 2 h) and immuno-stained for γ-H2AX foci. Representative images of γ-H2AX foci and the percentage of cells displaying γ-H2AX foci are shown.
Scale bar = 50 μm. (e) Western blot was used to test the levels of p-AMPK and γ-H2AX in H1299 cells stably expressing SRSF1 sh1 and control sh2, SRSF1 sh1 and AMPK sh1, or
control sh1 and control sh2, which were treated with or without IR. For all panels “*” indicated p b 0.05.
10 J. Sheng et al. / EBioMedicine xxx (xxxx) xxxlevels of p-AMPK and γ-H2AX were evidently increased in PTPMT1B-
expressing xenografts upon IR (Fig. 6d), suggesting that PTPMT1 splic-
ing does induce DNA damage to sensitize cancer cells to radiotherapy
in vivo.
To further test the clinical signiﬁcance of SRSF1-regulated splicing of
PTPMT1 in cancer patients, we examined the relative levels of twoPlease cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.007PTPMT1 isoforms in paired NSCLC samples and adjacent normal tissues
surgically collected from 6 patients. Compared to the paired normal tis-
sues, the relativemRNA levels of PTPMT1Bwere substantially decreased
in all tested primary NSCLC specimens (Fig. 6e) that had elevated ex-
pression of SRSF1 (Fig.S5a–b), suggesting a common decrease of
PTPMT1B expression despite obvious heterogeneity in different tumorTPMT1 alternative splicing to regulate lung cancer cell radioresistance,
11J. Sheng et al. / EBioMedicine xxx (xxxx) xxxspecimens. In support of our observations, analyses of RNA-seq datasets
from the TCGA consortium indicated that PTPMT1B levels were dramat-
ically decreased in 5 tumor types, including lung, head and neck, renal,
prostate and thyroid cancer (Fig. 6f).
We subsequently analyzed the datasets from large scale studies
[39–45], and found the level of PTPMT1A is signiﬁcantly elevated inPlease cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.007lung and breast cancers (Fig. 6g), which is positively correlated to
SRSF1 level (Fig. 6h). In addition, we used Kaplan-Meier Plotter to eval-
uate the overall survival of cancer patients with different PTPMT1A
levels usingdatasets from large scale screening [46]. As expected, higher
expression of PTPMT1A was related to poor overall survival in patients
with lung and breast cancer (Fig. 6i).TPMT1 alternative splicing to regulate lung cancer cell radioresistance,
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Radioresistance may lead to cancer recurrence and poor prognosis.
Many factors play vital roles in radioresistance. It has been reported
that EGFR overexpression is closely correlated to irradiation resistance,
thus the application of EGFR inhibitor can sensitize cancer cells to radio-
therapy [47–49]. In addition, activation of NF-kappa B is associatedwith
radioresistance in several kinds of cancers [50], whereas inhibition of
NF-kappa B improves sensitivity to irradiation [51]. αvβ3 integrin can
also mediates radioresistance of prostate cancer cells through regula-
tion of survivin [52]. Interestingly, radiation-activated CDC6 protein sta-
bility results in radioresistance via mediating senescence and EMT [53].
Deregulation of AS is one of most important molecular hallmarks of
cancer [7–10], however the detailed mechanisms and biological conse-
quences are still elusive. Notably, whether aberrant AS plays vital roles
in the development of radioresistance in cancer cells remains unknown.
Herewe report a novel function of SRSF1 in regulating radioresistance of
lung cancer cells. Previously, SRSF1 has been shown to control the splic-
ing of RON and BIN1, thus promoting breast cancer progression [26]. In
our model, for the ﬁrst time, we demonstrated that IR can elevate the
level of SRSF1, which in turn promote the splicing of PTPMT1 to the
long form, thereby reducing the level of p-AMPK. Such decrease inhibits
DNA damage, and confers cancer cells to resist to radiotherapy. Con-
versely, when the level of SRSF1 is decreased, it can switch the splicing
of PTPMT1 towards PTPMT1B. Strikingly, such splicing switch elevates
the level of p-AMPK, thus induces DNA double strand break, and sensi-
tizes lung cancer cells to radiotherapy (Fig. 6j). Altogether our results
represent a novel mechanism for how SRSF1 is involved in
radioresistance through modulating AS of new cancer related genes.
SRSF1 is a well-known splicing factor that can promote tumorigene-
sis via regulating alternative splicing, however, in addition to splicing
regulation, it has been previously reported that SRSF1 interacts with
translating ribosomes and promotes translation [23].By analyzing the
RNA-seq data, we found that translation regulation was also enriched
in the gene ontology analyses upon SRSF1 knockdown, suggesting that
SRSF1 may also contribute to radioresistance of cancer cells by regulat-
ing translation initiation and elongation.
Intriguingly, our data suggest that PTPMT1B can reduce the
clonogenic survival rate of lung cancer cells after IR. Consistently, the
level of PTPMT1B is reduced in lung cancer patients' samples. In addi-
tion, analyses of TCGA datasets also suggest that the splicing of
PTPMT1 is frequently changed in several cancer patients to decrease
PTPMT1B. Re-expression of PTPMT1B markedly elevated the level of
p-AMPK, thus inducing the DNA double-strand breaks. Therefore, ma-
nipulating PTPMT1 splicing may provide a novel approach to sensitize
cancer cells to radiotherapy. Particularly, PTPMT1 splicing is regulated
by SRSF1, an oncogenic splicing factor. Loss of SRSF1 increases the pro-
duction of PTPMT1B, which might in turn sensitize cancer cells to IR
through distinct signaling pathway.
However, the splicing of PTPMT1 towards the short isoformmay not
account for the radiosensitization totally. Other SRSF1-controlled splic-
ing events might also contribute the radioresistance of cancer cells.
Using RNA-seq, we also found that SRSF1 regulated some AS events of
genes associated with cell-cell adhesion andmitochondrial ATP synthe-
sis. For instance, SRSF1 controls splicing of MRPS28, which has been
demonstrated to participate in response to IR in a cervical cancer cellFig. 6. PTPMT1 splicing induces radiosensitivity in vivo and is correlatedwith survival in patien
the ﬂank of nudemice respectively. Micewere subsequently treatedwith orwithout 6 Gy IR. Pi
tumors measured every 5 days (error bars indicate ± SD). (c) The weights of the tumors were
Western blot was applied to determine the levels of p-AMPK and γ-H2AX in representative m
tumors and adjacent normal tissues were assayed to measure the splicing of PTPMT1 by qRT
PTPMT1 was examined in various cancers by analyzing the TCGA consortium containing RN
cancer. Oncomine was used to analyze previously collected data. The median, upper and lowe
values that were outside of the intra-quartile range. (h) Correlation of PTPMT1A and SRSF1 in
mean levels of PTPMT1A and SRSF1 were plotted, error bars indicate upper and lower qua
cancers bearing high or low PTPMT1A expression. (j) The model of how SRSF1 regulates radio
Please cite this article as: J. Sheng, Q. Zhao, J. Zhao, et al., SRSF1modulates P
EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.11.007line [54]. These data indicate that SRSF1modulatesmanyAS events crit-
ical to radio-resistance, which may provide a potential therapeutic ap-
proach to sensitize cancer cells to radiotherapy. But SRSF1 also has
several physiological functions to maintain cells in certain condition.
We may not want to completely deplete SRSF1. In this case, we might
use antisense oligos to switch the splicing of some key genes, such as
PTPMT1 for example. In addition, the application of antisense oligos
targeting several genes will provide a more robust effect to sensitize
cancer cells to radiotherapy.
Taken together, our data show that reduced SRSF1 mediates the AS
of PTPMT1 and other genes, which together may contribute to the sen-
sitization of cancer cells to radiotherapy. N90% of human genes undergo
alternative splicing, thus aberrant splicingplays a key role in tumorigen-
esis, as well as radioresistance of cancer cells to radiotherapy. Therefore,
detailed studies of deregulated splicing are important to provide new
insights in radioresistance of different cancers. Our study offers acritical
example of how a splicing factor can regulate vital AS events in
radioresistance of cancer cells, which can be potentially explored as a
new route of sensitizing cancer cells to radiotherapy.
5. Conclusions
In summary, we ﬁnd that SRSF1 regulates lung cancer cell
radioresistance through modulating PTPMT1 splicing. Reduced SRSF1
favors the production of short isoforms of PTPMT1 upon ionizing radia-
tion, which in turn promotes phosphorylation of AMPK, thereby induc-
ing DNA double-strand break to sensitize cancer cells to irradiation.
Additionally, the level of the short isoforms of PTPMT1 is decreased in
cancer samples, which is correlated to cancer patients' survival. Our
study provides mechanistic analyses of aberrant splicing in
radioresistance in lung cancer cells, and establishes SRSF1 as a potential
therapeutic target for sensitization of patients to radiotherapy.
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